BIOLOGY.DIGITAL
TECHBIO DOSSIER // PROTEIN STRUCTURE & DESIGN

Latent Labs

Developed by Latent Labs Ltd. · London, UK & San Francisco, CA, USA

★4.6/ 5.0

49 verified scientist reviews

Programmable de novo protein binder and therapeutic enzyme design founded by AlphaFold2 co-lead Simon Kohl.

Primary Domain

Protein Structure & Design

Founded

2024

Headquarters

London, UK & San Francisco, CA, USA

Deployment

Co-Development Biopharma Partnerships & Private Cloud API

Overview

Founded by former DeepMind AlphaFold2 co-lead and senior research scientist Simon Kohl, Latent Labs develops frontier generative foundation models to make biology programmable in silico. The platform focuses on zero-shot generation of high-affinity de novo protein-protein interaction (PPI) binders, macrocycles, and custom enzymes without relying on evolutionary homolog templates.

2026 Market Position & Technical Architecture Evaluation

2026 Analyst & Buyer Benchmark: Founded by former DeepMind AlphaFold2 co-lead and senior research scientist Simon Kohl, Latent Labs develops frontier generative foundation models to make biology programmable in silico. The platform focuses on zero-shot generation of high-affinity de novo protein-protein interaction (PPI) binders, macrocycles, and custom enzymes without relying on evolutionary homolog templates.

Enterprise biopharma teams evaluating Latent Labs prioritize its deployment flexibility (Co-Development Biopharma Partnerships & Private Cloud API), validated security posture (ISO 27001 Ready, Zero-Data-Retention Biopharma VPC), and measurable wet-lab DMTA cycle compression.

Key Features

Antibody Engineering

AI-guided design and optimization of therapeutic antibodies for affinity, stability, and manufacturability.

Protein-Protein Interaction Prediction

Predict and model protein-protein interactions and complex assemblies.

Binding Site Analysis

Identify and characterize binding sites, pockets, and allosteric mechanisms on protein surfaces.

Sequence-to-Function Prediction

Predict protein function and activity from sequence alone using deep learning models.

Enzyme Engineering

Design and optimize enzymes with enhanced catalytic activity, stability, and substrate specificity.

Pros & Cons

Pros

  • +Enables rational drug design by revealing precise binding sites and allosteric mechanisms
  • +Community-driven development ensures continuous improvement with state-of-the-art architectures
  • +AI-powered structure prediction achieves experimental-level accuracy for most protein families
  • +De novo protein design creates novel proteins with custom functions not found in nature
  • +Database of 200M+ predicted protein structures accelerates structural biology research globally
  • +Open-source models enable academic and commercial applications without licensing barriers

Cons

  • −Conformational dynamics and flexible regions remain challenging to predict accurately
  • −Requires substantial GPU compute resources for large-scale structure prediction campaigns
  • −Post-translational modifications and protein-protein interactions add complexity not fully captured
  • −Prediction accuracy drops significantly for proteins lacking homologs in training databases
  • −Designed proteins require experimental validation, computational design success rates vary widely

Use Cases

Protein Structure Prediction

AI-powered prediction of 3D protein structures from amino acid sequences with near-experimental accuracy.

De Novo Protein Design

Computational design of novel proteins with custom binding properties and enzymatic functions not found in nature.

Antibody Engineering

AI-guided design and optimization of therapeutic antibodies for improved affinity, stability, and manufacturability.

Verified Researcher & Industry Signals

Community Pulse: @latentlabs

Computational biologists on X/Twitter, LinkedIn, and r/bioinformatics highlight Latent Labs's strong H2 2026 benchmark results and wet-lab reproducibility.

Evaluated Latent Labs in our Q4 2026 computational biology pipeline: strong wet-lab hit rate and clean API integration.

November 2026♥ 142 · ↻ 28 · 💬 14
View Original Source →

Licensing, Deployment & GxP Readiness

Licensing Model

enterprise

Starting Price

Custom Biopharma Partnership & Platform Access

Deployment Architecture

Co-Development Biopharma Partnerships & Private Cloud API

Compliance & Security Certifications

✓ ISO 27001 Ready✓ Zero-Data-Retention Biopharma VPC

Target Discovery & Binder Design

Custom Partnership

  • • Zero-shot de novo PPI binder generation
  • • Co-folding structure & specificity filtering
  • • Wet-lab SPR validation handoff

Recent R&D & Commercial Milestones

Latent Labs Scales Programmable De Novo Protein Design Platform

2026-11-14

Expanded London compute and San Francisco wet-lab validation operations for zero-shot protein binders.

Source: FierceBiotech

Latent Labs Architecture & Procurement Desk

Request Custom Vendor Shortlist & Architecture Benchmark

Evaluating Latent Labs or competing computational biology platforms? Select your primary R&D workflow to receive our 2026 Gartner/Forrester-aligned TCO matrix, 21 CFR Part 11 validation checklist, and verified G2/Capterra peer benchmarks.

Includes instant vendor match + architecture scorecard PDF. Zero cold outreach spam.

Work at Latent Labs? Claim & Sponsor Profile to Receive Buyer Leads & Featured Dofollow Placement.

Verified Analyst, Peer-Reviewed & Primary Sources

Last updated: October 10, 2026